Announcements
- ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
- ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
- ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
- ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
More ▼
Key statistics
On Monday, Oric Pharmaceuticals Inc (4TZ:DUS) closed at 9.55, 91.77% above the 52 week low of 4.98 set on Oct 20, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.45 |
---|---|
High | 9.55 |
Low | 9.35 |
Bid | -- |
Offer | -- |
Previous close | 9.55 |
Average volume | 3.40 |
---|---|
Shares outstanding | 67.42m |
Free float | 60.98m |
P/E (TTM) | -- |
Market cap | 689.06m USD |
EPS (TTM) | -1.81 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 18:32 BST.
More ▼